Sodium Alginate antacid combination on quality of life, Tolerability and effectiveness in GERD patients
Not Applicable
- Conditions
- Health Condition 1: K210- Gastro-esophageal reflux disease with esophagitis
- Registration Number
- CTRI/2024/07/070568
- Lead Sponsor
- Alembic Pharmaceuticals Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Ages: = 18 years
2. Genders Eligible for Study: both Males and Females
3. Patients who received oral Sodium alginate antacid suspension in the past for the
management of GERD as per the local prescription data.
Exclusion Criteria
Patients those who had not received sodium alginate antacid suspension as per the local
prescription data
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method